Fianlimab plus Libtayo demonstrated persistent and significant clinical activity in patients with advanced melanoma.
Jax DiEugenio
Advertisement
Articles by Jax DiEugenio
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Will the end of enhanced ACA subsidies mean the beginning of a health insurance crisis?
2
Pharmacy leaders in ASHP survey worry about 340B program changes
3
FDA approves first postmenopausal libido treatment, Addyi
4
Johns Hopkins experts warn of potentially severe flu season, measles elimination status faces risk
5